CJC-1295 (No-DAC) + Ipamorelin Pen
Pre-filled research pen containing 10mg CJC-1295 + 10mg Ipamorelin (20mg total), a dual-peptide growth hormone secretagogue formulation. For research purposes only.
BodyPharm UAE supplies CJC-1295 (No-DAC) + Ipamorelin Pen for research purposes across Dubai, Abu Dhabi, Sharjah, and the wider UAE. All compounds are sourced to strict purity standards and shipped with secure, trackable delivery.
Research Areas
Designed for advanced research in these areas
Growth hormone axis modulation research
Tissue remodelling and recovery pathway studies
Metabolic rate and body composition analysis
Sleep architecture and circadian rhythm research
Certificate of Analysis
Verified by in-house laboratory testing
In-House Testing
Body Pharm laboratory
Report
#260114
Batch
CJIP9837
Purity
99.09%
Concentration
5.2 mg/ml
Precision Engineered
This dual-peptide formulation combines CJC-1295, a synthetic GHRH analogue studied for its role in amplifying growth hormone-releasing hormone signalling, with Ipamorelin, a selective ghrelin-receptor agonist investigated for its ability to stimulate pulsatile GH release without significantly elevating cortisol or prolactin levels. Together, they represent a widely studied combination in growth hormone axis research.
Research Background
CJC-1295 (No-DAC), or Modified GRF 1-29, is a GHRH analogue with substitutions that resist enzymatic degradation. Lacking the Drug Affinity Complex of the DAC form, it has a short half-life and drives pulsatile, rather than sustained, somatotroph activation, which is why it is studied as a tool for physiological GH pulse dynamics. Ipamorelin is a selective GHSR-1a agonist studied for pulsatile GH release with minimal cortisol, prolactin, or ACTH effect.
Pairing a GHRH analogue with a GHSR-1a agonist is of interest because the two act on distinct receptor pathways; combined exposure has been reported to raise GH pulse amplitude and IGF-1 signalling in rodent models. Supplied for in vitro and laboratory research only.
Research references
- Teichman S.L. et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
Frequently Asked Questions
A dual formulation of Ipamorelin (a selective GHSR-1a agonist) and CJC-1295 (a GHRH analogue), both studied in growth-hormone-axis research. For laboratory research only.
BodyPharm sells Ipamorelin CJC-1295 strictly for research purposes. Customers are responsible for understanding applicable regulations in their jurisdiction.
Ipamorelin is studied for selective, pulsatile GH release with little cortisol or prolactin effect. This product is the no-DAC CJC-1295 (Modified GRF 1-29), short half-life and pulsatile in research models unlike the sustained DAC form; combined exposure has raised IGF-1 in rodent studies.
They act on distinct receptors (GHRH receptor and GHSR-1a); together they may amplify GH pulsatility, a useful tool for somatotropic-axis studies.
One pre-filled research pen with 10mg CJC-1295 (No-DAC, Modified GRF 1-29) and 10mg Ipamorelin (20mg total), with a batch Certificate of Analysis reference.
What Researchers Say
How was our customer service? Did your delivery arrive on time? Was the product what you expected? Let us know and receive 10% off and free delivery with your next order.
Specifications
Premium-grade formulation for advanced research
20mg
Total Content
≥99%
Purity
Pre-filled Research Pen
Format
2-8°C Refrigerated
Storage
-
Volume Options
CJC-1295 & Ipamorelin
Active Ingredient
Modified GRF 1-29
CJC-1295 (No-DAC) Compound Name
863288-34-0
CJC-1295 (No-DAC) CAS
~3368 g/mol
CJC-1295 (No-DAC) MW
Ipamorelin
Ipamorelin Compound Name
170851-70-4
Ipamorelin CAS
~711.9 g/mol
Ipamorelin MW
HPLC (in-house)
Verification
Ready to order?
CJC-1295 (No-DAC) + Ipamorelin Pen
AED 900
Same day delivery across the UAE